Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
Follow RVTY
Alert me
Revvity Inc. (RVTY) P/E ratio
As of 5 November 2026, Revvity Inc. (RVTY) trades at a P/E ratio of 71.9×. Over the past ten years it has ranged from 13.4× (May 2021) to 93.6× (May 2024); the current reading is higher than 92% of that period. That is above the Diagnostics & Research industry median of 34.5× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 46.5× | (7.90%) |
| FY2024 | 50.5× | 151.53% |
| FY2023 | 20.1× | (34.85%) |
| FY2022 | 30.8× | 23.84% |
| FY2021 | 24.9× | 12.37% |
| FY2020 | 22.1× | (53.47%) |
| FY2019 | 47.6× | 29.07% |
| FY2018 | 36.9× | 31.72% |
| FY2017 | 28.0× | 12.53% |
| FY2016 | 24.9× | (12.69%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 72.8× | 37.42% |
| Jun 2026 | 53.0× | 26.39% |
| Mar 2026 | 41.9× | (9.88%) |
| Dec 2025 | 46.5× | 5.61% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 25.0× |
| QGEN QIAGEN N.V. compare | 26.1× |
| LH Labcorp Holdings Inc. compare | 29.5× |
| ICLR ICON PLC compare | 34.5× |
| MEDP Medpace Holdings, Inc. compare | 34.6× |
| ILMN Illumina, Inc. compare | 35.6× |
| RVTY Revvity Inc. | 71.9× |
| CRL Charles River Laboratories International, Inc. compare | 300× |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on RVTY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement